Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body. Eventually, the disease can cause the nerves themselves to deteriorate or become permanently damaged.
Multiple Sclerosis Therapeutics Market contains market size and forecasts of Multiple Sclerosis Therapeutics in Global, including the following market information:
- Global Multiple Sclerosis Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Multiple Sclerosis Therapeutics market was valued at 17530 million in 2021 and is projected to reach US$ 20010 million by 2028, at a CAGR of 1.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Beta Interferon Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Multiple Sclerosis Therapeutics include Novartis, Teva Pharmaceuticals, Sanofi Genzyme, Bayer, Pfizer, Biogen Idec, Merck and AbbVie, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Multiple Sclerosis Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Multiple Sclerosis Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Multiple Sclerosis Therapeutics Market Segment Percentages, by Type, 2021 (%)
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agents
- Others
Global Multiple Sclerosis Therapeutics Market, by Distribution Channel, 2017-2022, 2023-2028 ($ millions)
Global Multiple Sclerosis Therapeutics Market Segment Percentages, by Distribution Channel, 2021 (%)
- Hospital Pharmacies
- Retail Pharmacies
- e-Commerce
Global Multiple Sclerosis Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Multiple Sclerosis Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Multiple Sclerosis Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
- Key companies Multiple Sclerosis Therapeutics revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Novartis
- Teva Pharmaceuticals
- Sanofi Genzyme
- Bayer
- Pfizer
- Biogen Idec
- Merck
- AbbVie
Industry Market Size
